Wednesday's Health Winners & Losers
Health stocks fell Wednesday, hit by the continuing effects of a bum trial, and a handful of disappointing earnings.
The bright spot was Encysive (ENCY), whose shares more than doubled after Pfizer (PFE) agreed to buy the troubled company for $2.35 a share, or about $195 million. The deal represents a more than 100% premium to Encysive's closing share price Tuesday of $1.08. Shares added $1.20 to $2.27.
Shares of Pfizer, which will gain rights to Encysive's pipeline and pulmonary arterial hypertension drug Thelin, lost 10 cents to $22.47.
On the down side, Onyx (ONXX) lost ground for the second straight day following news that the biotech and partner Bayer AG ended a late-stage trial on their drug Nexavar in lung cancer patients. The stock, which lost more than 20% on Tuesday, sank another $2.35, or 6.9%, to $30.80, on Wednesday.Onyx contributed to a drop in the Nasdaq biotechnology index, which fell 0.7% to 788.08. Elsewhere, Inverness Medical Innovations (IMA) plunged 16% even after the company reported better-than-expected fourth-quarter results. Inverness posted a loss of 19 cents a share, compared to a profit of 15 cents a share a year earlier. But on an adjusted basis, the company said its earnings per share rose to 40 cents from 34 cents a year earlier. Analysts surveyed by Thomson Financial were looking for 38 cents a share, on average. Inverness shares fell $7.04 to $36.83. Matria Healthcare (MATR) -- which agreed last month to be acquired by Inverness for $900 million -- shed $1.94, or 6.6%, to $27.45. Medical-device company Xtent (XTNT) also declined on its fourth-quarter report. The company posted a loss of $11.9 million, or 52 cents a share, based on 22.8 million weighted average shares outstanding. In the year-ago quarter the company had a loss of $7.2 million, or $2.46 a share, based on 2.9 million weighted average shares outstanding. Its stock gave up $1.40 to $8.11. Kindred Healthcare (KND) shares tumbled on a disappointing first-quarter forecast. The health care services company said after the bell Tuesday that its fourth-quarter profit fell to $16.3 million, or 43 cents a share, from $22.1 million, or 56 cents a share, in the year-earlier period. Excluding items, Kindred Healthcare did surpass the Thomson Financial average analyst target by two cents, earning 51 cents a share. For the first quarter, however, the company forecast earnings of 22 cents to 27 cents a share, well below analysts' target of 39 cents. Shares declined $2.58, or 10%, to $23.25. One stock higher on earnings was Cyberonics (CYBX), which soared 17% after the device maker posted a narrower-than-expected quarterly loss and announcing plans to buy back up to 1 million shares. The company reported a loss of $1 million, or 4 cents a share, narrowed from a loss of $19.4 million, or 76 cents a share, a year earlier. Analysts polled by Thomson Financial were expecting a loss of 9 cents a share. The company's sales declined, but a 12% cut in staff helped to push down operating expenses. Shares of Cyberonics rose $1.68 to $11.41.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV